Cancer combo trial pulled before it even started
NCT ID NCT07511972
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This was a phase 2 study planned to test a new drug called NGM707 combined with the immunotherapy pembrolizumab in people with advanced or metastatic solid tumors, specifically colorectal cancer. The goal was to see if the combination could shrink tumors and to check for side effects. However, the study was withdrawn before any participants were enrolled, so no results are available.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- NGM707 plus pembrolizumab
- What this could lead to
- If it worked, this combination could shrink tumors or slow cancer growth in people with advanced solid tumors that have not responded to other treatments.
- What could go wrong
- This trial was withdrawn before enrolling any participants, so there is no data on safety or effectiveness. The combination may cause side effects or fail to work better than existing options.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED OR METASTATIC SOLID TUMOR MALIGNANCY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Cancer-Fighting virus shrink tumors when chemo fails?
- Blood test may let cancer patients take safe breaks from immunotherapy
- Pee test could spot colon cancer early in africa
- Sniffing out cancer: new breath test could spot colon cancer before it spreads
- New biopsy method may predict cancer spread without surgery
- New combo therapy shows promise for Tough-to-Treat colon cancer